![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 38, 35682-35687, September 20, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of
Received for publication, April 29, 2002, and in revised form, July 8, 2002
Calcium plays a regulatory role in
several aspects of protein trafficking in the cell. Both vesicle fusion
and vesicle formation can be inhibited by the addition of calcium
chelators. Because the effects of calcium chelators have been studied
predominantly in cell-free systems, it is not clear exactly which
transport steps in the secretory pathway are sensitive to calcium
levels. In this regard, we have studied the effects of calcium
chelators on both anterograde and retrograde protein transport in whole cells. Using both cytochemical and biochemical analyses, we find that
the anterograde-directed exit of vesicular stomatitis virus G
protein and the retrograde-directed exit of Shiga toxin from the Golgi
apparatus are both inhibited by calcium chelation. The exit of
vesicular stomatitis virus G from a pre-Golgi compartment and the exit
of Shiga toxin from an endosomal compartment are sensitive to the
membrane-permeant calcium chelator 1,2-bis(2-amino phenoxy)ethane-N,N,N',N'-tetraacetic
acid-tetrakis (acetoxymethyl ester) (BAPTA-AM). By contrast,
endoplasmic reticulum exit and endocytic internalization from the
plasma membrane are not affected by BAPTA. Together, our data show that
some, but not all, trafficking steps in the cell may be regulated by
calcium. These studies provide a framework for a more detailed analysis
of the role of calcium as a regulatory agent during protein transport.
The modulation of cytosolic calcium levels serves as an
important signaling system for cell regulation (1). Protein
transport within the secretory pathway is among the processes regulated by calcium. The best characterized role for calcium in vesicular transport is in the calcium-triggered fusion of synaptic and
secretory vesicles at the plasma membrane (2-4).
Calcium-regulated vesicle fusion and fusion reactions in the
constitutive secretory pathway have similar molecular mechanisms. For
example, both types of fusion reactions are mediated or regulated by
SNARE1 proteins, as well as
rab- and sec1/munc18-related
proteins (5). Recent studies indicate that a regulatory role for
calcium may also extend to fusion reactions in the constitutive
secretory pathway.
Both major organelles of the early secretory pathway, the endoplasmic
reticulum and the Golgi apparatus, are known to be cellular calcium
stores (6, 7). Secretory vesicles have also been shown recently to act
as a dynamic calcium store (8). Two classes of
ATP-dependent pump proteins maintain high lumenal calcium
concentrations in these organelles. The sarco/endoplasmic reticulum
calcium ATPase (SERCA)-type pumps are found both on the ER and
the Golgi (9-11). Pmr1p was identified as a Golgi calcium pump in
yeast (12), and mutations in the mammalian isoform lead to
Hailey-Hailey disease (13). Studies analyzing the subcellular
localization of calcium indicate that calcium concentrations are
particularly high in the Golgi region of cells and that calcium
gradients could exist among organelles of the secretory pathway (6,
14). Both the ER and the Golgi apparatus have also been shown to have
inositol 1,4,5-trisphosphate receptors for the triggered release
of calcium during cell signaling (1, 15). Specific calcium binding or sequestering proteins have been localized to each organelle. The calcium-binding chaperone proteins calreticulin and calnexin function in the ER (16, 17). At least three lumenal calcium-binding proteins,
Cab45, CALNUC (nucleobindin), and p54/NEFA have been localized
to the Golgi (11, 18, 19). The presence of calcium stores and specific
calcium-binding proteins in secretory organelles has revived the notion
that calcium or calcium gradients are important for regulating the
constitutive secretory pathway (20).
Studies on ER to Golgi transport in yeast and in semi-intact
(perforated) cells have indeed indicated a role for calcium in this
trafficking step (21-24). Regulation by calcium has also been implicated in homotypic vacuolar fusion (25), in late endosome-lysosome heterotypic fusion and the reformation of lysosomes from hybrid organelles (26), and in fusion between endosomal compartments (27).
There are several lines of evidence showing that calcium is important
for the function of the Golgi apparatus. Most directly, calcium
chelators have been shown to block intra-Golgi protein transport
in vitro (28). The brefeldin A-induced retrograde transport
from the Golgi apparatus to the endoplasmic reticulum is also affected
by calcium chelation (29). Calmodulin has been shown to mediate the
effects of calcium on several of these fusion or transport reactions
(25, 28, 30). Interestingly, the calcium chelator BAPTA is often
found to be more effective than EGTA at inhibiting these membrane
fusion reactions (25-27). BAPTA has a much faster on rate for calcium
binding than does EGTA. This observation is frequently interpreted to
indicate that calcium transients or gradients rather than steady-state
calcium levels regulate these processes.
We have recently reported that in addition to regulating membrane
fusion reactions, calcium may play a role in regulating the coating or
uncoating of transport vesicles. We found that treating cells
with the membrane-permeable calcium chelator BAPTA-AM led to
the dissociation of the COPI vesicle coat protein, coatomer, from the Golgi apparatus (31). Using cell-free Golgi binding assays, we
also observed that the addition of BAPTA led to the rapid dissociation
of coatomer from previously coated Golgi membranes. As with fusion,
BAPTA was more effective than EGTA at mediating this effect. The
addition of calcium chelators appears to affect a step in vesicle coat
assembly after the recruitment of ADP-ribosylation factor, the
small GTP-binding protein that triggers coat assembly.
The previous studies strongly implicate a role for calcium in
regulating transport through the constitutive exocytic and endocytic protein transport pathways. These studies have utilized cell-free systems, and thus it is still not clear to what extent calcium modulates transport through the secretory system in whole cells. As a
step toward clarifying the role of calcium in transport, we have
analyzed the effects of membrane-permeant calcium chelators on both
anterograde and retrograde protein transport through the secretory
pathway. This study indicates that select transport steps are sensitive
to calcium transients or gradients.
Materials--
Tissue culture media were obtained through the
Diabetes and Endocrinology Research Center, University of Iowa. The
construct pT77-SLT-B-Glyc-KDEL was obtained as gifts from Drs. B. Goud
and A. Girod. BAPTA-AM and EGTA-AM were purchased from Molecular Probes (Eugene, OR). The following antibodies were used in this study: anti-rat mannosidase II (Berkeley Antibody Co., Richmond, CA), polyclonal anti-VSV G (Medical & Biological Laboratories Co., Naka-Ku
Nagoya, Japan), P5D4 monoclonal anti-VSV G (32), anti-BiP (Affinity
Bioreagents Inc., Golden, CO), and anti-biotin (Sigma).
VSV G Protein Transport Assay--
The cell line Gts-NRK (a gift
from Dr. V. Malhotra) that stably expresses the temperature-sensitive
ts045-VSV G was maintained by growth at a permissive temperature
(32 °C) in Immunofluorescence--
Gts-NRK cells were plated onto glass
cover slips, and after 24 h the cells were washed with
phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde, and
permeabilized using 0.1% Triton X-100 for 4 min at room temperature.
The formaldehyde was quenched with 50 mM ammonium chloride
for 10 min at room temperature. The cells were washed three times with
PBS and blocked with 2.5% donkey serum in PBS for 1 h at room
temperature. Appropriate dilutions of the anti VSV G, anti-mannosidase
II, and anti-BiP antibodies in the blocking buffer were added to the
cells for 1 h at room temperature. The cells were washed three
times with PBS and incubated with fluorescein isothiocyanate-conjugated
anti-rabbit and Texas Red-conjugated anti-mouse secondary antibodies in
blocking buffer for 1 h at room temperature. The cells were washed
three times, mounted on slides, and analyzed on a confocal microscope
(Bio-Rad).
Electron Microscopy--
Gts-NRK cells were incubated with or
without 50 µM BAPTA-AM in Shiga Toxin Transport--
To construct a vector expressing
Shiga toxin B-fragment (STB) with an N-glycosylation site,
PCR was employed. PCR primers T7 (5'-TAA TAC GAC TCA CTA TAG
GG-3') and STB-WT1 (5'-AAT GGA TCC TCA TTC AGA GCT AGT AGA A-3') were
used with plasmid pT77-SLT-B-Glyc-KDEL. The resulting fragment was
verified by sequencing and then cloned into the pET11a vector
(Stratagene, La Jolla, CA) to make pETSTB-Glyc.
The recombinant Shiga toxin B-fragment was overexpressed in the
BL21(DE3)pLysS bacterial strain (Stratagene) and purified using ion
exchange chromatography as described (33) except that a High Q column
(Bio-Rad) was used in place of Mono Q column. The STB was labeled using
activated Cy2 for fluorescence microscopy (Amersham Biosciences; HP7
9NA) or activated biotin for Western blot analysis according to the
manufacturer's instructions. The cells were incubated for 30 min in
the presence of 2 µg/ml labeled STB. The cells were then washed three
times with fresh medium and incubated for various times as described in
the figure legends.
Western Blotting and Glycosylation Analysis--
The proteins
were fractionated using SDS-PAGE and blotted onto polyvinylidene
difluoride membranes using standard protocol for the Bio-Rad minigel
and blotting apparatuses. Following the transfer, the membranes were
incubated with appropriate dilutions of the indicated primary
antibodies. The signal was visualized using horseradish
peroxidase-conjugated secondary antibodies (Bio-Rad) and ECL (Amersham Biosciences).
The treatment of VSV G protein with endoglycosidase H (Calbiochem) was
done according to the manufacturer's instructions. For STB
glycosylation analysis, the toxin was labeled with biotin (Pierce)
using appropriate molar ratio of biotin to protein. STB-biotin was
detected by Western blotting using anti-biotin antibodies. In some
experiments, the cells were incubated in the presence of 1 µg/ml
tunicamycin 1 h before the addition of STB.
BAPTA Blocks Transport from an ER/Golgi Intermediate Compartment to
the Golgi but Does Not Affect Exit from the ER--
We used a NRK cell
line constitutively expressing a temperature-sensitive VSV G (ts045) to
analyze the effects of calcium chelation on anterograde protein
transport through the secretory pathway. VSV G (ts045) is trapped in
the ER at the restrictive temperature (39.5 °C) but is transported
normally through the Golgi apparatus to the plasma membrane at the
permissive temperature (32 °C). The transport of VSV G was monitored
using both fluorescence microscopy (Fig.
1) and by determining the glycosylation
state of the VSV G (Fig. 2). Following a
16-h incubation at the restrictive temperature, the VSV G is localized
to a dispersed ER compartment (Fig. 1A). When cells were
switched to a permissive temperature (32 °C) for 15 min, the VSV G
was relocated to the juxtanuclear Golgi compartment (Fig.
1B). After 90 min at the permissive temperature, VSV G was
found dispersed in small punctate and tubular structures and at the
cell surface (Fig. 1C). In some cells, a small amount of
residual Golgi-like staining was also observed. ER-localized, core-glycosylated VSV G protein is sensitive to deglycosylation by
endoglycosidase H (endo H), whereas complex oligosaccharides generated
by processing in the Golgi are endo H-resistant. Endo H digestion of
cell extracts following the incubation at the restrictive temperature
confirms that the VSV G from these cells is completely endo H-sensitive
and thus has not been processed by the Golgi (Fig. 2A,
lanes 1 and 2). Following a 90-min incubation at
the permissive temperature, all of the VSV G in cells is endo
H-resistant, indicating that it has been transported through the Golgi
(Fig. 2A, lanes 3 and 4).
To determine what effect calcium chelation had on VSV G transport, we
treated cells with the membrane-permeant calcium chelator BAPTA-AM at
various times relative to the switch from the restrictive to the
permissive temperature. When BAPTA-AM was added to the cells either 90 min (not shown) or 30 min (Fig. 1D) prior to the switch from
the restrictive to the permissive temperature, we observed a marked
difference in the localization of VSV G. Instead of localizing to the
dispersed post-Golgi structures and the plasma membrane, VSV G was now
found to localize to large, brightly labeled perinuclear punctate
structures (Fig. 1, compare C and D).
We examined whether the VSVG-containing punctate structures observed
upon BAPTA-AM treatment were a pre- or post-Golgi compartment by
testing whether the VSV G was endo H-resistant under this condition. Fig. 2A shows that when BAPTA-AM was added at least 30 min
prior to switching the cells to the permissive temperature, the
majority of the VSV G was endo H-sensitive and thus had not reached the Golgi (lanes 5-8). Fig. 2B shows that the block
in ER to Golgi transport by BAPTA-AM is reversed when intracellular
calcium levels are restored by the addition of the calcium ionophore
A23187 and CaCl2 to the medium. Together, the fluorescence
microscopy and biochemical analysis demonstrate that when BAPTA-AM is
added prior to the switch to the permissive temperature, VSV G is
blocked in a pre-Golgi compartment.
The punctate perinuclear structures could result from an alteration in
ER morphology caused by the presence of BAPTA. Alternatively, in the
presence of BAPTA, the VSV G might exit the ER and then become trapped
in a punctate ER/Golgi intermediate compartment. We examined the
morphology of both the ER and the Golgi following BAPTA treatment to
differentiate between these possibilities. As shown in Fig.
3, immunofluorescence using
anti-mannosidase II antibodies to label the Golgi (C and
D) and anti-Bip antibodies to label the ER (A and
B) revealed that BAPTA treatment had little or no effect on
the morphology of either of these organelles. In particular, no
punctate Bip-positive ER elements analogous to the VSV G-containing
structures shown in Fig. 1D were observed. As expected from
our previous studies (31), coatomer was found to be dissociated from
the Golgi after treatment with BAPTA-AM (not shown). Ultrastructural
characterization also reveals that the morphology of the Golgi
apparatus is not overtly affected in cells following treatment with the
calcium chelator (Fig. 3, E and F). The electron
micrographs show that the Golgi is of similar size and retains a
stacked structure after treatment with BAPTA for 90 min. Together, our
results reveal that addition of BAPTA-AM and thus a decrease in
cytosolic free calcium does not block the exit of VSV G from the ER.
However, it prevents VSV G transport to the Golgi apparatus and causes
the accumulation of VSV G in a punctate perinuclear ER/Golgi
intermediate compartment.
The Exit of VSV G from the Golgi Is Blocked by BAPTA--
The
addition of BAPTA-AM to the cells simultaneously with the switch to the
permissive temperature caused VSV G to accumulate in a juxtanuclear
structure reminiscent of the Golgi apparatus (Fig. 1E).
Colocalization studies revealed that indeed, under this condition, VSV
G localization overlaps almost completely with the Golgi marker
mannosidase II (Fig. 4). Fig.
2A shows that when BAPTA-AM is added at the same time as the
temperature switch, all of the VSV G becomes endo H-resistant
(lanes 9 and 10), confirming that it has now
reached the Golgi. Together, the data indicate two distinct blocks in
anterograde protein transport of VSV G in the presence of BAPTA-AM: one
block in an ER/Golgi intermediate compartment and a second block either
within or from the Golgi apparatus.
We were not able to detect any additional effects of calcium chelation
on VSV G transport in post-Golgi transport steps by adding BAPTA-AM
after the temperature switch. The addition of BAPTA-AM 30 min after the
temperature switch caused a small amount of VSV G to accumulate in the
Golgi of some cells, but there was no obvious accumulation of VSV G in
any additional structure that might represent a transport intermediate
between the Golgi and the plasma membrane (Fig. 1, compare C
and F). This finding is consistent with a previous study
showing that there are no defects in protein transport when a calcium
ionophore and EGTA are added to cells after a 1-h pulse-chase (34).
Both calcium-sensitive membrane fusion reactions and COPI coat
assembly share the property that they are more sensitive to BAPTA than
to EGTA (25-27, 31). Because BAPTA has a much faster on-rate for
calcium binding, this difference has been interpreted to indicate that
a calcium transient or gradient may be involved. If the effects of
BAPTA-AM in the whole cell analysis reflect the effects of BAPTA in
cell-free fusion and budding assays, we predicted that whole cell
trafficking might also be more sensitive to BAPTA than to EGTA. Thus,
we compared the effects of EGTA-AM and BAPTA-AM on VSV G transport.
Fig. 5 shows that there was no obvious
accumulation of VSV G in the Golgi or in a pre-Golgi compartment upon
treatment with EGTA-AM. Furthermore, biochemical analysis revealed that
VSV G became endo H-resistant regardless of when EGTA-AM was added
relative to the switch to the permissive temperature (Fig.
6). Although 50 µM BAPTA-AM
was a more effective inhibitor than 50 µM EGTA-AM, 3 mM EGTA, which is not membrane permeant, inhibited VSVG
transport to the Golgi when added together with a calcium ionophore
(Fig. 2B, lanes 5 and 6). These
findings support the model that BAPTA-AM inhibits protein transport by
disrupting intracellular calcium levels (see "Discussion").
Distinct Steps in Retrograde Protein Transport Are Sensitive to
BAPTA--
Although the majority of proteins move through the
secretory pathway in an anterograde direction, retrograde protein
transport also plays an important role in the function of the secretory pathway. Retrograde transport is necessary for the retrieval of escaped
resident organelle proteins, for the recycling of proteins that
function in transport, and for quality control and protein degradation.
Some bacterial toxins such as cholera toxin and Shiga toxin have proven
to be good tools for studying retrograde protein transport through
secretory organelles (35-38). These toxins are endocytosed into cells
and are then transported from endosomes through the Golgi apparatus to
the ER (35, 39, 40). The toxins are transported from the lumen of the
ER into the cytosol where they then exert their toxic effect (40).
We have used the Shiga-like toxin B subunit to analyze the effects of
BAPTA-AM on retrograde protein transport. For these experiments,
recombinant STB was purified and covalently labeled with Cy2 (see
"Experimental Procedures"). Vero cells were incubated with the
labeled toxin for 30 min to allow the toxin to internalize. The
noninternalized toxin was then washed away with fresh medium, and the
cells were allowed to grow for an additional 0.5-16 h. The location of
STB in the cell was monitored by fluorescence microscopy (Fig.
7). In addition, we used a recombinant
form of Shiga toxin that was engineered to contain an
N-glycosylation site (33, 41) to detect the arrival of the
STB in the ER biochemically (Fig. 8).
Fluorescence microscopy shows that the internalized STB first appeared
in punctate endosomal compartments and then within 2 h became
concentrated in the Golgi (Fig. 7). Diffuse ER-like staining was also
observed by microscopy after 2-h incubations. As a more precise
indicator of STB arrival in the ER, we examined its glycosylation
state. Consistent with previous studies (33), we observed three
distinct STB bands on Western blots following retrograde transport of
STB through the secretory pathway (Fig. 8). We confirmed that the
uppermost band corresponds to the core-glycosylated form of STB by
treating cells with tunicamycin to block core glycosylation (Fig.
8A, lanes 6-10). Fig. 8A shows that
STB starts to arrive in the ER at about 2 h after the addition of
the toxin (lane 2). We observed a peak of STB glycosylation
at about 4 h after addition of the toxin to the cells (Fig.
8A, lane 3).
We determined the effects of calcium chelation on the retrograde
transport of STB by adding BAPTA-AM to the cells at different times
relative to the addition of the STB. We found that when BAPTA-AM was
added at the same time or prior to the addition of STB, the toxin was
internalized but appeared to accumulate in punctate endosomal
compartments (Fig. 7). Although the Golgi had normal morphology under
these conditions (Fig. 3), we never observed colocalization of STB with
the Golgi when BAPTA-AM was added early (not shown). Determination of
the glycosylation state of STB confirmed that it remained
unglycosylated and thus did not reach the ER when BAPTA-AM was added to
the cells at the same time as STB (Fig. 8B, lane
2). The results indicate that although internalization of STB into
an endosomal compartment is not affected by calcium chelation, its
transport from an endosomal compartment to the Golgi is blocked by the
presence of the calcium chelator. Previous studies indicate that STB is
transported directly from early endosomes to the Golgi, bypassing the
late endosomes (42). Our results indicate a requirement for calcium in
this direct trafficking step.
We found that addition of BAPTA-AM up to 60 min after the addition of
STB completely blocked the transport of STB to the ER as revealed by
its failure to be glycosylated (Fig. 8B, lanes 2,
4, and 6). When BAPTA-AM was added 90 or 120 min
after STB, glycosylated STB was observed, indicating that at least some
STB had moved beyond a BAPTA-sensitive transport step and arrived in
the ER (Fig. 8B, lanes 8 and 10).
Interestingly, by comparing the localization of STB with its
glycosylation state, we found that although STB is not glycosylated
when BAPTA is added 60 min after the addition of STB to the cells (Fig.
8B, lane 6), some of the STB is localized to a
juxtanuclear Golgi compartment (Fig. 7). We interpret this to indicate
that some of the STB has arrived at the Golgi by 60 min and that BAPTA
has inhibited a Golgi to ER retrograde transport step. Thus, as was the
case for anterograde transport, it appears that some retrograde
transport steps, such as the internalization (endocytosis) of STB, are
insensitive to calcium chelation, whereas other steps, such as endosome
to Golgi apparatus and Golgi to ER transport, are inhibited in the
presence of the calcium chelator BAPTA.
Previous studies have shown that both membrane fusion reactions
and vesicle assembly reactions are inhibited by the calcium chelator
BAPTA. Because these studies have relied on the cell-free reconstitution of these processes, we have set out to determine whether
steps in constitutive anterograde and retrograde protein transport are
affected by calcium chelators in whole cells. The use of the membrane
permeant analogs, BAPTA-AM and EGTA-AM, is particularly effective for
these studies because the analogs do not bind calcium until they have
entered the cell and the acetoxymethyl ester moiety has been
hydrolyzed. Because normal extracellular calcium levels are maintained,
the cells remain attached to their substrate, allowing relatively
normal cell morphology to be maintained. This has allowed the combined
immunohistochemical and biochemical analysis we report in this paper.
This combined approach has revealed that at least four resolvable steps
are inhibited by treating cells with BAPTA-AM. The BAPTA-sensitive
steps during anterograde transport of VSV G through the secretory
pathway include intermediate compartment to Golgi transport and exit
from the Golgi apparatus. During retrograde transport through the
secretory pathway, we find that transport of STB from the endosome to
the Golgi is inhibited as well as transport from the Golgi apparatus to
the ER. At least two transport steps were found to be resistant to
BAPTA-AM. These include endocytosis of STB from the plasma membrane and
the exit of VSV G from the ER.
A surprising aspect of this and many other studies examining the
effects of calcium chelators on reactions involved in protein transport
is that BAPTA acts more effectively as an inhibitor than EGTA. One
possibility is that the fast initial binding rate of BAPTA is able to
buffer calcium transients that are not buffered by EGTA. A second
possibility is that under biological conditions (or within certain
biological microenvironments), the calcium-binding constant for BAPTA
is in fact smaller than for EGTA. A third explanation is that BAPTA
acts in some manner other than by chelating calcium. For example, BAPTA
has been shown to act as an inhibitor of phospholipase D (43).
Our results, in conjunction with other studies, are most consistent
with BAPTA disrupting protein transport by acting as a calcium
chelator. First, for the cell-free studies (28, 31) and for ER to Golgi
transport in whole cells (Fig. 2), the addition of calcium reverses the
effects of BAPTA. Thus, if BAPTA is acting directly on a protein, it is
only the non-calcium-bound form that is able to do so. Second, we find
that disrupting intracellular calcium levels in a BAPTA-independent
manner with an ionophore and extracellular EGTA also disrupts ER to
Golgi transport (Fig. 2B). Similarly, in cell-free studies
on membrane fusion and Golgi transport where BAPTA is more effective
than EGTA, calmodulin has been shown to be involved (25, 28, 30). This
provides independent evidence of a role for calcium in reactions
disrupted specifically by BAPTA. Finally, we showed previously that
although BAPTA is more effective than EGTA at uncoating COPI
vesicles, EGTA did have an effect when added at a higher concentration
(31).
Our results indicate that several transport steps in the cell are
affected by chelating calcium with BAPTA. Because both vesicle fusion
and vesicle formation are potentially regulated by calcium, an
important remaining question is which of the transport blocks result
from an effect on membrane fusion and which ones result from an
effect on vesicle formation. Regulating vesicle formation or vesicle
fusion independently could lead to an accumulation or a depletion of
vesicles. For example, increasing the rate of fusion without a
concomitant increase in the rate of vesicle formation would lead to
vesicle depletion. An interesting possibility is that both processes
are regulated simultaneously at calcium-sensitive transport steps. By
coordinating the rate of vesicle fusion and the rate of vesicle
formation and uncoating through similar calcium-mediated regulatory mechanisms, the problem of vesicle accumulation or depletion might be avoided. Future studies on the role of calcium on
fusion reactions and in vesicle coating and uncoating reactions in the
secretory pathway should provide additional insight into this regulation.
We thank Dr. Lois Weismann for helpful discussion.
*
This work was supported by grants (to M. S.) from the
American Cancer Society, The American Heart Association Heartland
Affiliate, and the Roy J. Carver Charitable Trust.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. E-mail:
mark-stamnes@uiowa.edu.
Published, JBC Papers in Press, July 11, 2002, DOI 10.1074/jbc.M204157200
The abbreviations used are:
SNARE, soluble
N-ethylmaleimide-sensitive factor attachment protein
receptors;
ER, endoplasmic reticulum;
BAPTA-AM, 1,2-bis(2-amino
phenoxy)ethane-N,N,N',N'-tetraacetic
acid-tetrakis (acetoxymethyl ester);
VSV, vesicular stomatitis virus;
PBS, phosphate-buffered saline;
STB, Shiga toxin B-fragment;
NRK, normal rat kidney;
endo H, endoglycosidase H.
Selective Effects of Calcium Chelators on Anterograde and
Retrograde Protein Transport in the Cell*
,
¶
Physiology & Biophysics and
§ Internal Medicine, Roy J. and Lucille A. Carver
College of Medicine, The University of Iowa,
Iowa City, Iowa 52242
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-minimum essential medium plus 5% fetal calf
serum. The cells were incubated for 14-16 h at a restrictive
temperature (39.5 °C) to accumulate VSV G protein in the ER and
processed for immunofluorescence. For VSV G protein transport assay,
the cells were incubated at 39.5 °C for 14-16 h, and then VSV G
protein was released from the temperature block by switching the cells
to 32 °C medium containing 10 µg/ml cycloheximide. The cells were
incubated for 15 or 90 min at (32 °C) and processed for
immunofluorescence. BAPTA-AM or EGTA-AM was added at the indicated
times by replacing the medium with medium containing 50 µM BAPTA-AM or 50 µM EGTA-AM plus 10 µg/ml cycloheximide. Where indicated, 2 µM A23187
(Sigma), 3 mM EGTA, or 5 mM CaCl2
were also added to the medium.
-minimum essential medium
for 90 min at 39.5 °C. The cells were fixed in 2.5% glutaraldehyde,
post-fixed in 1% OsO4, dehydrated, and embedded in
Spurr's embedding medium. Ultrathin sections stained with uranyl
acetate and lead citrate were examined with an H-7000 transmission
electron microscope.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (139K):
[in a new window]
Fig. 1.
Anterograde VSV G transport is blocked in the
presence of BAPTA. Shown are confocal micrographs of Gts-NRK cells
in which the VSV G protein has been immunolabeled. The cells were grown
at 39.5 °C for 16 h to accumulate ts-045 VSV G in the ER
(A). The cells were then shifted to the permissive
temperature (32 °C) for 15 min (B) or for 90 min
(C-F). The cells were either untreated (A-C) or
treated with 50 µM BAPTA-AM at the times minus 30 min
(D), 0 min (E), or plus 30 min (F),
relative to the shift to the permissive temperature. The bar
indicates 10 µM.

View larger version (32K):
[in a new window]
Fig. 2.
The early addition of BAPTA-AM blocks VSV G
transport to the Golgi. Shown are Western blots of Gts-NRK cell
lysates probed with anti-VSV G antibodies. A, prior to the
lysis the cells had been incubated at the restrictive temperature
(39.5 °C) for 16 h (lanes 1 and 2) or
incubated at the restrictive temperature for 16 h and then shifted
to the permissive temperature (32 °C) for 90 min (lanes
3-12). As in Fig. 1, BAPTA-AM was omitted (lanes 1-4)
or added (lanes 5-12) at the indicated time relative to the
temperature switch. Endoglycosidase H (EndoH) was added to
the samples where indicated to determine whether Golgi processing of
oligosaccharide chains had occurred. B, cells were treated
exactly as in A except that A23187 (2 µM),
CaCl2 (5 mM), or EGTA (3 mM) was
added 30 min prior to the temperature switch in addition to or instead
of the BAPTA-AM as indicated. N/A, not
applicable.

View larger version (96K):
[in a new window]
Fig. 3.
BAPTA treatment does not alter the morphology
of the ER or Golgi. Shown are confocal microgaphs
(A-D) and electron micrographs (E and
F) from untreated (A, C, and
E) or BAPTA-AM-treated (B, D, and
F) NRK cells. Fixed and permeabilized cells were decorated
with anti-Bip (A and B) to label the ER or
anti-mannosidase II to label the Golgi (C and D).
E and F show electron micrographs containing
views of stacked Golgi membranes. The bar in D
indicates 10 µM, and the bar in F
indicates 50 nm.

View larger version (16K):
[in a new window]
Fig. 4.
VSV G localizes to Golgi membranes when BAPTA
is added at the same time as the temperature switch. Shown is a
confocal micrograph of Gts-NRK cells labeled for VSV G and
anti-mannosidase II (Mann II). A merged image of the two
signals demonstrates colocalization. VSV G was accumulated in
the ER by incubation at 39.5 °C, and the cells were switched to
32 °C for 90 min. BAPTA-AM had been added at the same time as the
switch to the permissive temperature. The bar indicates 10 µM.

View larger version (139K):
[in a new window]
Fig. 5.
EGTA-AM is less effective at disrupting
anterograde protein transport. Shown are confocal micrographs of
Gts-NRK cells labeled with anti VSV G antibodies. The cells were
incubated at 39.5 °C and then shifted to 32 °C for 15 min
(A and B) or 90 min (C and
D). The cells were either left untreated (A and
C) or exposed to 50 µM EGTA-AM (B
and D) starting at 30 min prior to the temperature switch.
The bar indicates 10 µM.

View larger version (14K):
[in a new window]
Fig. 6.
EGTA-AM does not block anterograde transit of
VSV G through the Golgi apparatus. Shown are Western blots of
Gts-NRK cell lysates probed with anti-VSV G antibodies. Prior to the
lysis, the cells had been incubated at the restrictive temperature
(39.5 °C) or incubated at the restrictive temperature and shifted to
the permissive temperature (32 °C) as in Fig. 2. EGTA-AM was omitted
or added at the indicated time relative to the temperature switch.
Endoglycosidase H (EndoH) was added to the samples where
indicated to determine whether Golgi processing of oligosaccharide
chains had occurred.

View larger version (47K):
[in a new window]
Fig. 7.
Retrograde transport of Shiga toxin B subunit
is blocked in the presence of BAPTA-AM. Shown are fluorescence
micrographs of Vero cells that were incubated for 30 min at 37 °C
with Cy-2-labeled STB, washed, and then incubated for an additional
2 h in the absence of the toxin. BAPTA-AM was added at the
indicated time relative to the addition of the STB-Cy2.

View larger version (44K):
[in a new window]
Fig. 8.
BAPTA-AM blocks the arrival of STB in the
ER. Shown are Western blot analyses of Vero cell lysates following
incubations with STB-biotin. A, cells were incubated for 30 min with STB-biotin, washed, and incubated for the indicated times in
the absence of STB. The incubations were done in the presence and the
absence of tunicamycin to identify the band resulting from core
glycosylation in the ER (glyc-STB). B, cells were
incubated for 30 min with STB-biotin followed by a 4-h chase in the
absence of STB. Either dimethyl sulfoxide (DMSO) solvent or
BAPTA-AM were added at the indicated times relative to the addition of
the STB-biotin. The BAPTA-AM or dimethyl sulfoxide was present
throughout the remainder of the 4-h chase period.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Bootman, M. D.,
Lipp, P.,
and Berridge, M. J.
(2001)
J. Cell Sci.
114,
2213-2222[Medline]
[Order article via Infotrieve]
2.
Lin, R. C.,
and Scheller, R. H.
(2000)
Annu. Rev. Cell Dev. Biol.
16,
19-49[CrossRef][Medline]
[Order article via Infotrieve]
3.
Brunger, A. T.
(2001)
Curr. Opin. Struct. Biol.
11,
163-173[CrossRef][Medline]
[Order article via Infotrieve]
4.
Hu, K.,
Carroll, J.,
Fedorovich, S.,
Rickman, C.,
Sukhodub, A.,
and Davletov, B.
(2002)
Nature
415,
646-650[CrossRef][Medline]
[Order article via Infotrieve]
5.
Jahn, R,
and Sudhof, T. C.
(1999)
Annu. Rev. Biochem.
68,
863-911[CrossRef][Medline]
[Order article via Infotrieve]
6.
Pinton, P.,
Pozzan, T.,
and Rizzuto, R.
(1998)
EMBO J.
17,
5298-5308[CrossRef][Medline]
[Order article via Infotrieve]
7.
Petersen, O. H.,
Tepikin, A.,
and Park, M. K.
(2001)
Trends Neurosci.
24,
271-276[CrossRef][Medline]
[Order article via Infotrieve]
8.
Mitchell, K. J.,
Pinton, P.,
Varadi, A.,
Tacchetti, C.,
Ainscow, E. K.,
Pozzan, T.,
Rizzuto, R.,
and Rutter, G. A.
(2001)
J. Cell Biol.
155,
41-51 9.
Pozzan, T.,
Rizzuto, R.,
Volpe, P.,
and Meldolesi, J.
(1994)
Physiol. Rev.
74,
595-636 10.
Clapham, D. E.
(1995)
Cell
80,
259-268[CrossRef][Medline]
[Order article via Infotrieve]
11.
Lin, P., Le-,
Niculescu, H.,
Hofmeister, R.,
McCaffery, J. M.,
Jin, M.,
Hennemann, H.,
McQuistan, T., De,
Vries, L.,
and Farquhar, M. G.
(1998)
J. Cell Biol.
141,
1515-1527 12.
Antebi, A.,
and Fink, G. R.
(1992)
Mol. Biol. Cell
3,
633-654[Abstract]
13.
Sudbrak, R.,
Brown, J.,
Dobson-Stone, C.,
Carter, S.,
Ramser, J.,
White, J.,
Healy, E.,
Dissanayake, M.,
Larregue, M.,
Perrussel, M.,
Lehrach, H.,
Munro, C. S.,
Strachan, T.,
Burge, S.,
Hovnanian, A.,
and Monaco, A. P.
(2000)
Hum. Mol. Genet.
9,
1131-1140 14.
George, C. H.,
Kendall, J. M.,
Campbell, A. K.,
and Evans, W. H.
(1998)
J. Biol. Chem.
273,
29822-29829 15.
Taylor, R. S.,
Jones, S. M.,
Dahl, R. H.,
Nordeen, M. H.,
and Howell, K. E.
(1997)
Mol. Biol. Cell
8,
1911-1931 16.
Jakob, C. A.,
Chevet, E.,
Thomas, D. Y.,
and Bergeron, J. J.
(2001)
Results Probl. Cell Differ.
33,
1-17[Medline]
[Order article via Infotrieve]
17.
Johnson, S.,
Michalak, M.,
Opas, M.,
and Eggleton, P.
(2001)
Trends Cell Biol.
11,
122-129[CrossRef][Medline]
[Order article via Infotrieve]
18.
Scherer, P. E.,
Lederkremer, G. Z.,
Williams, S.,
Fogliano, M.,
Baldini, G.,
and Lodish, H. F.
(1996)
J. Cell Biol.
133,
257-268 19.
Morel-Huaux, V. M.,
Pypaert, M.,
Wouters, S.,
Tartakoff, A. M.,
Jurgan, U.,
Gevaert, K.,
and Courtoy, P. J.
(2002)
Eur. J. Cell Biol.
81,
87-100[CrossRef][Medline]
[Order article via Infotrieve]
20.
Sambrook, J. F.
(1990)
Cell
61,
197-199[CrossRef][Medline]
[Order article via Infotrieve]
21.
Beckers, C. J. M.,
and Balch, W. E.
(1989)
J. Cell Biol.
108,
1245-1256 22.
Baker, D.,
Wuestehube, L.,
Schekman, R.,
Botstein, D.,
and Segev, N.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
355-359 23.
Schwaninger, R.,
Beckers, C. J. M.,
and Balch, W. E.
(1991)
J. Biol. Chem.
1266,
13055-13063
24.
Pind, S. N.,
Nuoffer, C.,
McCaffery, J. M.,
Plutner, H.,
Davidson, H. W.,
Farquhar, M. G.,
and Balch, W. E.
(1994)
J. Cell Biol.
125,
239-252 25.
Peters, C.,
and Mayer, A.
(1998)
Nature
396,
575-580[CrossRef][Medline]
[Order article via Infotrieve]
26.
Pryor, P. R.,
Mullock, B. M.,
Bright, N. A.,
Gray, S. R.,
and Luzio, J. P.
(2000)
J. Cell Biol.
149,
1053-1062 27.
Mayorga, L. S.,
Beron, W.,
Sarrouf, M. N.,
Colombo, M. I.,
Creutz, C.,
and Stahl, P. D.
(1994)
J. Biol. Chem.
269,
30927-30934 28.
Porat, A.,
and Elazar, Z.
(2000)
J. Biol. Chem.
275,
29233-29237 29.
Ivessa, N. E., De,
Lemos-Chiarandini, C.,
Gravotta, D.,
Sabatini, D. D.,
and Kreibich, G.
(1996)
J. Biol. Chem.
270,
25960-25967
30.
Colombo, M. I.,
Beron, W.,
and Stahl, P. D.
(1997)
J. Biol. Chem.
272,
7707-7712 31.
Ahluwalia, J. P.,
Topp, J. D.,
Weirather, K.,
Zimmerman, M.,
and Stamnes, M.
(2001)
J. Biol. Chem.
276,
34148-34155 32.
Kreis, T. E.
(1986)
EMBO J.
5,
931-941[Medline]
[Order article via Infotrieve]
33.
Johannes, L.,
Tenza, D.,
Antony, C.,
and Goud, B.
(1997)
J. Biol. Chem.
272,
19554-19561 34.
Duncan, J. S.,
and Burgoyne, R. D.
(1996)
Biochem. J.
317,
487-493[Medline]
[Order article via Infotrieve]
35.
Johannes, L.,
and Goud, B.
(2000)
Traffic
1,
119-123[CrossRef][Medline]
[Order article via Infotrieve]
36.
Girod, A.,
Storrie, B.,
Simpson, J. C.,
Johannes, L.,
Goud, B.,
Roberts, L. M.,
Lord, J. M.,
Nilsson, T.,
and Pepperkok, R.
(1999)
Nat. Cell Biol.
1,
423-430[CrossRef][Medline]
[Order article via Infotrieve]
37.
Mallard, F.,
Tang, B. L.,
Galli, T.,
Tenza, D.,
Saint-Pol, A.,
Yue, X.,
Antony, C.,
Hong, W.,
Goud, B.,
and Johannes, L.
(2002)
J. Cell Biol.
156,
653-664 38.
Luna, A.,
Matas, O. B.,
Martinez-Menarguez, J. A.,
Mato, E.,
Duran, J. M.,
Ballesta, J.,
Way, M.,
and Egea, G.
(2002)
Mol. Biol. Cell
13,
866-879 39.
Sandvig, K.,
Garred, O.,
Prydz, K.,
Kozlov, J. V.,
Hansen, S. H.,
and van Deurs, B.
(1992)
Nature
358,
510-512[CrossRef][Medline]
[Order article via Infotrieve]
40.
Sandvig, K.,
Llorente, A.,
Rodal, S. K.,
Eker, P.,
Garred, O.,
Stahlhut, M.,
and van Deurs, B.
(2000)
Eur. J. Cell Biol.
79,
447-457[CrossRef][Medline]
[Order article via Infotrieve]
41.
White, J.,
Johannes, L.,
Mallard, F.,
Girod, A.,
Grill, S.,
Reinsch, S.,
Keller, P.,
Tzschaschel, B.,
Echard, A.,
Goud, B.,
and Stelzer, E. H.
(1999)
J. Cell Biol.
147,
743-760 42.
Mallard, F.,
Antony, C.,
Tenza, D.,
Salamero, J.,
Goud, B.,
and Johannes, L.
(1998)
J. Cell Biol.
143,
973-990 43.
Coorssen, J. R.,
and Haslam, R. J.
(1993)
FEBS Lett.
316,
170-174[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. Walchli, S. S. Skanland, T. F. Gregers, S. U. Lauvrak, M. L. Torgersen, M. Ying, S. Kuroda, A. Maturana, and K. Sandvig The Mitogen-activated Protein Kinase p38 Links Shiga Toxin-dependent Signaling and Trafficking Mol. Biol. Cell, January 1, 2008; 19(1): 95 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Yamasaki, K. Tani, A. Yamamoto, N. Kitamura, and M. Komada The Ca2+-binding Protein ALG-2 Is Recruited to Endoplasmic Reticulum Exit Sites by Sec31A and Stabilizes the Localization of Sec31A Mol. Biol. Cell, November 1, 2006; 17(11): 4876 - 4887. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hehnly, D. Sheff, and M. Stamnes Shiga Toxin Facilitates Its Retrograde Transport by Modifying Microtubule Dynamics Mol. Biol. Cell, October 1, 2006; 17(10): 4379 - 4389. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Chen, R. V. Fucini, L. Lacomis, H. Erdjument-Bromage, P. Tempst, and M. Stamnes Coatomer-bound Cdc42 regulates dynein recruitment to COPI vesicles J. Cell Biol., May 9, 2005; 169(3): 383 - 389. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ohba, E. C. Schirmer, T. Nishimoto, and L. Gerace Energy- and temperature-dependent transport of integral proteins to the inner nuclear membrane via the nuclear pore J. Cell Biol., December 20, 2004; 167(6): 1051 - 1062. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Andrade, H. Zhao, B. Titus, S. Timm Pearce, and M. Barroso The EF-Hand Ca2+-binding Protein p22 Plays a Role in Microtubule and Endoplasmic Reticulum Organization and Dynamics with Distinct Ca2+-binding Requirements Mol. Biol. Cell, February 1, 2004; 15(2): 481 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. O'Callaghan, B. Hasdemir, M. Leighton, and R. D. Burgoyne Residues within the myristoylation motif determine intracellular targeting of the neuronal Ca2+ sensor protein KChIP1 to post-ER transport vesicles and traffic of Kv4 K+ channels J. Cell Sci., December 1, 2003; 116(23): 4833 - 4845. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Duran, F. Valderrama, S. Castel, J. Magdalena, M. Tomas, H. Hosoya, J. Renau-Piqueras, V. Malhotra, and G. Egea Myosin Motors and Not Actin Comets Are Mediators of the Actin-based Golgi-to-Endoplasmic Reticulum Protein Transport Mol. Biol. Cell, February 1, 2003; 14(2): 445 - 459. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||